Heiko Kranz
Research Subjects
Research Interests
Heiko Kranz has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
C. Guthmann
Pharmaceutical Development, Bayer Schering Pharma AG, Berlin, Germany
1 shared publicationErol Yilmaz
Freie Universität Berlin
1 shared publicationGayle A. Brazeau
University of Florida
1 shared publication- Juergen Siepmann
Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France
1 shared publication K. Jürgens
1 shared publicationM. Pinier
1 shared publication
Latest Publications
- 1 October 2009
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 380 (1-2) , 112-119
Evaluation of the drug release patterns and long term stability of aqueous and organic coated pellets by using blends of enteric and gastrointestinal insoluble polymers
- 1 October 2009
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 380 (1-2) , 112-119
Evaluation of the drug release patterns and long term stability of aqueous and organic coated pellets by using blends of enteric and gastrointestinal insoluble polymers
- 1 October 2009
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 73 (2) , 302-309
Drug release from MCC- and carrageenan-based pellets: Experiment and theory
- 1 October 2009
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 73 (2) , 302-309
Drug release from MCC- and carrageenan-based pellets: Experiment and theory
- 1 July 2008
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 34 (2-3) , 164-172
Structure formation and characterization of injectable drug loaded biodegradable devices: In situ implants versus in situ microparticles
- 1 July 2008
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 34 (2-3) , 164-172
Structure formation and characterization of injectable drug loaded biodegradable devices: In situ implants versus in situ microparticles
- 28 December 2007
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 69 (2) , 667-674
Development of a novel osmotically driven drug delivery system for weakly basic drugs
- 28 December 2007
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 69 (2) , 667-674
Development of a novel osmotically driven drug delivery system for weakly basic drugs
- 30 October 2007
- Published by Springer Nature in Pharmaceutical Research
- Vol. 25 (6) , 1347-1354
In Vitro and In Vivo Drug Release from a Novel In Situ Forming Drug Delivery System
The objective of this work was to investigate the influence of various preparation and formulation parameters on the in vitro and in vivo release of bupivacaine hydrochloride from an injectable in situ forming microparticle system (ISM). The in vitro drug release of ISM was investigated as a function of various formulation and process parameters and was compared to the drug release from in situ forming implants and conventional microparticles. In vivo studies were carried out in male Sprague–Dawley rats. Upon contact with an aqueous medium, the internal polymer phase of the ISM system solidified and formed microparticles. The initial drug release from ISM systems was reduced with decreasing polymer phase/external oil phase ratio. An advantage of the ISM system compared to in situ implant systems was the significantly reduced burst effect, resulting in drug release profiles comparable to microparticles prepared by conventional methods. The in vivo drug release studies were in good agreement with the in vitro drug release. With the ISM system, the analgesic effect of the bupivacaine hydrochloride was prolonged when compared to the injection of a drug solution or drug-polymer solution. ISM are an attractive alternative for parenteral drug delivery systems.
- 30 October 2007
- Published by Springer Nature in Pharmaceutical Research
- Vol. 25 (6) , 1347-1354
In Vitro and In Vivo Drug Release from a Novel In Situ Forming Drug Delivery System
The objective of this work was to investigate the influence of various preparation and formulation parameters on the in vitro and in vivo release of bupivacaine hydrochloride from an injectable in situ forming microparticle system (ISM). The in vitro drug release of ISM was investigated as a function of various formulation and process parameters and was compared to the drug release from in situ forming implants and conventional microparticles. In vivo studies were carried out in male Sprague–Dawley rats. Upon contact with an aqueous medium, the internal polymer phase of the ISM system solidified and formed microparticles. The initial drug release from ISM systems was reduced with decreasing polymer phase/external oil phase ratio. An advantage of the ISM system compared to in situ implant systems was the significantly reduced burst effect, resulting in drug release profiles comparable to microparticles prepared by conventional methods. The in vivo drug release studies were in good agreement with the in vitro drug release. With the ISM system, the analgesic effect of the bupivacaine hydrochloride was prolonged when compared to the injection of a drug solution or drug-polymer solution. ISM are an attractive alternative for parenteral drug delivery systems.